Upstream Bio, Inc.

NASDAQ:UPB

Biotechnology

Healthcare
$2.08 +1.63%

+$0.10 today

Market cap
$114.01M
Beta
1.11
P/E (TTM)
-2.2
EPS (TTM)
-$2.89
52W Low $5.85High $33.68

Volume 1.24M

Average 0.66M

UPB Sales of Investments

Cash received from selling or redeeming investments.

Upstream Bio, Inc.NASDAQ: UPB

Sales of Investments · Q1 FY2026 · quarter ended Mar 2026

Sales of investments grows, but more slowly than its trailing trend

Q1 FY2026 sales of investments of $56.82M rose 7.9% year over year, behind the +20.1% change in trailing-twelve-month sales of investments. Sequentially, it fell 41.6% from the prior quarter.

Context

  • Sales of investments amounted to 10251.0% of revenue in FY2025, up 477.4 pp from a year earlier.
  • Sales of investments increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +7.9% toward the trailing-twelve-month pace of +20.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$56.82M-41.6% QoQ
Last fiscal yearDec 2025
$292.56M+26.3% YoY
LTMMar 2026
$296.71M+20.1% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+7.9%——
1 year+26.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
292.56M USD
Year-over-year change
+26.3%

Sales of Investments vs competitors

How UPB compares with its peers on the latest reported figures

  • Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +20.1% is the 4th highest of 8, against a peer median of +2.6%.
  • Sales of investments amounts to 8931.7% of revenue for UPB, versus a peer median of 352.1%.
UPB Competitors
Sales of Investments for UPB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$981.03M USD+2.6%+17.3%1484.3%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$459.13M USD+22.8%+16.3%211.4%
NVAXNovavax, Inc.LTM Mar 2026$458.02M USD-5.9%—76.8%
SYRESpyre Therapeutics, Inc.LTM Sep 2026$445.96M USD+31.2%+56.7%492.8%
RLAYRelay Therapeutics, Inc.LTM Jun 2026$369.36M USD-5.8%-3.9%3568.7%
UPBUpstream Bio, Inc.LTM Mar 2026$296.71M USD+20.1%—8931.7%
ZBIOZenas BioPharma, Inc.LTM Mar 2026$296.16M USD+1470.5%——
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026$228.84M USD-8.8%+11.1%—
PHVSPharvaris N.V.LTM Sep 2026€0 EUR———
WVEWave Life Sciences Ltd.LTM Mar 2026$0 USD——0.0%
Peer median (excluding UPB) —+2.6%+16.3%352.1%

Competitors are the stored peer set for UPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(23.87M)(20.54M)(62.81M)(143.44M)
Depreciation & Amortization7K60K89K(1.31M)
Deferred Income Tax0000
Stock-Based Compensation1.28M3.43M6M10.33M
Change in Working Capital3.41M(4.31M)1.87M589K
Accounts Receivables(412K)314K(515K)(55K)
Inventory0000
Accounts Payables462K1.28M2.02M(1.28M)
Other Working Capital3.36M(5.9M)371K1.93M
Other Non-Cash Items149K(16.57M)(4.33M)561K
Operating Cash Flow(19.02M)(37.93M)(59.17M)(133.28M)
Capital Expenditures(82K)(144K)(511K)(165K)
Acquisitions (Net)0000
Purchases of Investments0(128.99M)(290.61M)(385.88M)
Sales of Investments046.29M231.64M292.56M
Other Investing Activities0000
Investing Cash Flow(82K)(82.84M)(59.49M)(93.48M)
Debt Repayment0000
Common Stock Issued9.96M129.55M272.72M2.44M
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities(37K)118K(3.74M)0
Financing Cash Flow9.96M129.55M418.91M2.44M
Effect of Forex Changes0000
Net Change in Cash(9.14M)8.78M300.25M(224.31M)
Free Cash Flow(19.1M)(38.07M)(59.68M)(133.28M)

Upstream Bio, Inc.

NASDAQ:UPB

Intrinsic Alpha fair value

Locked

Current Price

$2.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.